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Cancer is currently the second leading cause of death and disability after cardiovascular disease. Worldwide, 
more than 1.6 million new cases of lung cancer are 
diagnosed annually.1,2 Lung cancer is the most common 
cause of cancer-related death in men and is second in this 
regard in women. In Europe, the overall 5-yr survival rate 
among patients with lung cancer is only 10%; among those 
undergoing surgery, survival is 40%.3
Because of the disease process and side effects of treat-
ment, patients with lung cancer often experience numerous 
symptoms, including pain, shortness of breath, weakness, 
weight loss, trouble sleeping, and depression.4,5 Reduction 
in physical activity is often observed, which contributes to a 
decrease in fitness and exercise capacity, a decrease in mus-
cle mass and strength, and a decline in pulmonary function 
and respiratory muscle strength.6-8
It has been generally observed that patients with lung 
cancer can safely participate in physical activity at any stage 
of the disease and its treatment.9-11 Additionally, evidence 
has been presented that physical activity reduces the risk of 
several forms of cancer12 and the risk of cancer recurrence 
by up to 40%.13 Physical training may extend the life of 
patients, prevent the occurrence of other chronic diseases, 
and reduce the symptoms of cancer.12,14 Statements of the 
American Thoracic Society and the European Respiratory 
Society conclude that pulmonary rehabilitation (PR) reduc-
es dyspnea and improves both exercise capacity and quality 
of life.15
The main objective of oncology rehabilitation is to pro-
mote functional independence and to facilitate the patient’s 
adaptation to the changing conditions of life as a result of 
the disease and its treatments.16 Physical training in on-
cology is generally supervised; after an initial assessment, 
suitable exercises and tasks of movement are selected to 
create an individual rehabilitation program with due regard 
to the disease stage, the type of therapy, and the patient’s 
motivation.17,18
The aim of this study was to assess the impact of exercise 
training in patients with non–small cell lung cancer during 
chemotherapy on several outcomes in comparison to an un-
trained, sedentary control group (CG).
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Purpose: The aim of this study was to perform a randomized 
trial to assess the impact of exercise training in patients with 
non–small cell lung cancer during chemotherapy on several out-
comes in comparison to a control group (CG).
Methods: The exercise training group (ETG) consisted of 
20 patients and the CG consisted of 10 patients. In the ETG, 
a 4-wk in-hospital exercise training program was performed in 
2-wk cycles interspersed with consecutive rounds of chemother-
apy with cytostatic drugs. The exercise training program was in-
dividualized and included warm-up, respiratory muscle exercise, 
training on a cycle ergometer or treadmill, and Nordic walking. 
CG participants were assessed before and after 6 wk of chemo-
therapy alone.
Results: Comparing pre- and post-intervention values, the ETG 
demonstrated an increase in 6-min walk distance (486 ± 92 vs 
531 ± 103 m, P = .01). In a battery of physical performance 
tests: Up and Go Test (6.3 ± 1.0 vs 6.0 ± 1.1 sec, P = .01); 
chair stand (13.3 ± 2.8 vs 14.3 ± 3.4 repetitions, P = .001); 
and arm curl (18.4 ± 3.1 vs 20.4 ± 3.5 repetitions, P = .001) all 
improved significantly. Spirometry values also improved: FEV1 
% predicted (76 ± 16 vs 84 ± 15, P = .01), FVC % predicted 
(87 ± 14 vs 95 ± 13, P = .01), and FEV1/FVC (73 ± 13% vs 
76 ± 12%, P = .04). The exercise training was well tolerated, 
without any adverse events due to exercise. There were no signif-
icant improvements in the CG.
Conclusions: This study suggests that planned, individual-
ized, and supervised exercise programs in patients with ad-
vanced lung cancer during chemotherapy are a practical and 
beneficial intervention for enhancing mobility and physical 
fitness.
Key Words:  chemotherapy • exercise training • lung cancer • 
pulmonary function tests
Figure 1. Flow of study interventions. Day 1: eligibility criteria, informed consent, baseline assessments: physical measures, lung function testing, and 
evaluation of dyspnea (MRC, BDI, Borg Scale), randomization, qualification for the exercise training program; afternoon: admission for chemotherapy. 
Day 7-20: exercise training program for the ETG (thick solid line). Day 21: admission for chemotherapy. Day 28-41: exercise training program for the 
ETG. Day 42, end of interventions: follow-up assessment includes physical measures, lung function testing, and evaluation of dyspnea (mMRC, BDI, 
Borg scale). Abbreviations: BDI, Baseline Dyspnea Index; ETG, exercise training group; mMRC, modified Medical Research Council questionnaire; 
PV, platidiam-vinorelbine chemotherapy treatment; V, vinorelbine chemotherapy treatment.
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METHODS
PARTICIPANTS
The research study took place at the Independent Public 
Clinical Hospital No. 3 of the Medical University of Silesia 
in Katowice, from October 2012 to February 2015. The 
study was approved by the Ethics Committee of Silesian 
Medical University (KNW/0022/KB1/184a/I/11/12). All pa-
tients signed a written consent to participate in the research. 
The research was registered in the Australian New Zealand 
Clinical Trials Registry (ACTRN12616001512415).
The study included 40 patients diagnosed with non–
small cell lung cancer (NSCLC) at stages IIIB or IV, who 
were disqualified from surgery. The diagnosis was estab-
lished within 6 wk prior to enrollment and was confirmed 
by histology. Patients were included in the study if they had 
the ability to perform the 6-min walk test (6MWT), were 
World Health Organization performance status 0-1, were 
able to complete questionnaires, and had willingness to 
participate in an exercise training program. Patients were 
deemed not eligible if they had uncontrolled hypertension 
or unstable coronary artery disease, anemia (hemoglobin 
<10 g/dL), severe osteoarthritis, or bone or central nervous 
system metastases.
Participants were randomly assigned, with a 2:1 as-
signment, to either the exercise training group (ETG) or 
the CG (utilizing computer-generated random numbers): 
26 patients were assigned to the ETG and 14 patients were 
assigned to the CG. CG participants were assessed before 
and after 6 wk of chemotherapy alone. In the ETG, a 4-wk 
in-hospital exercise training program was used on the ba-
sis of rehabilitation program in chronic obstructive pul-
monary disease (COPD),19  which was performed in 2-wk 
cycles interspersed with consecutive rounds of chemothera-
py: cisplatidiam 80 mg/m2 on the first day and vinorelbine 
25 mg/m2 on the first and eighth days (patients in the CG 
received an identical chemotherapy regimen). This exercise 
program was conducted in the hospital under the super-
vision of a physiotherapist and contained elements of en-
durance training, breathing exercises, weight training, and 
fitness exercise.
The study was scheduled by a physiotherapist from 
the Institute of Physiotherapy, not related to the hospital, 
who generated the random allocation sequence using the 
hospital chart number as the identifier for each partici-
pating patient. The patients were enrolled, assigned, and 
supervised during the hospital stay by the doctors work-
ing in hospital departments who were not related to the 
study. Outcomes were obtained using chart review by a 
physiotherapist trained in the abstraction of the desired 
outcomes from the medical records who was blinded to 
the oncology treatment.
OUTCOME MEASURES
The study flow chart is presented in Figure 1. Potentially 
eligible participants were provided with a thorough review 
of the study by the study coordinator and willingness to 
participate was assessed. After obtaining consent, medi-
cal records were reviewed to determine eligibility. Eligible 
patients were randomized to either the ETG or CG. At 
baseline (Day 1) and at the end of the study (Day 42), the 
following factors were assessed in both groups: (1) exer-
cise performance was assessed by the 6MWT distance, 
performed according to the American Thoracic Society 
2002 guidelines20; (2) spirometry was performed using the 
Jaeger-Masterlab (Erich–Jaeger) to assess forced expiratory 
volume in 1 sec (FEV1), forced vital capacity (FVC), and the 
ratio of the 2 measures (FEV1/FVC) according to European 
Respiratory Society recommendations,21 and these values 
were compared with normal values from the European 
Coal and Steel Community22; (3) dyspnea was evaluated 
using the modified Medical Research Council (mMRC) 
questionnaire,23 Baseline Dyspnea Index (BDI),24 and Borg 
dyspnea scale25; (4) functional fitness was assessed with 
the Fullerton test,26 which is composed of 6 components—
chair stand, arm curl, chair sit-and-reach, up and go, back 
scratch, and 6MWT.
INTERVENTIONS
In the CG, there was a 6-wk period between the initial and 
final assessments; during wk 1 and wk 4, patients under-
went scheduled in-hospital chemotherapy. No exercise in-
tervention was performed in this group.
 Based on the initial 6MWT and spirometry results, pa-
tients in the ETG participated in two 2-wk inpatient ex-
ercise training programs, supervised by a certified phys-
iotherapist. In Poland, it is common practice for patients 
with lung cancer to be admitted to the hospital for 2 wk of 
in-hospital rehabilitation. Between these 2 exercise training 
periods of time, patients underwent scheduled in-hospital 
chemotherapy.
Table 1
Characteristics Participants Completing the Studya
Exercise Training 
Group (n = 20)
Control Group 
(n = 10)
Age, yr 59.1 ± 6.8 61.3 ± 8.8
Male 18 ± 90 9 ± 90
BMI, kg/m2 25.0 ± 4.1 26.2 ± 2.9
Comorbidities
   COPD 12 (60) 5 (50)
   Coronary artery disease history 3 (15) 1 (10)
   Heart failure history 0 (0) 0 (0)
   Diabetes mellitus 6 (30) 3 (30)
Smoking history
   Current 0 (0) 0 (0)
   Former 15 (75) 7 (70)
   Never 5 (25) 3 (30)
WHO performance status
   0 3 (15) 1 (10)
   1 17 (85) 9 (90)
Diagnosis
   Adenocarcinoma 14 (70) 7 (70)
   Squamous cell carcinoma 6 (30) 3 (30)
TNM status
   T2N2M0 16 (80) 8 (80)
   T2N2M1 4 (20) 2 (20)
Tumor stage
   IIIB 16 (80) 8 (80)
   IV 4 (20) 2 (20)
Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; TNM, 
tumor node metastasis; WHO, World Health Organization.
aData are reported as mean ± standard deviation or number (%).
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Patients enrolled in supervised exercise training were 
assigned different intensities based on initial 6MWT and 
spirometry assessments. Patients participated in exercise 
sessions 5 times/wk. Sessions consisted of (1) 30 min of fit-
ness and respiratory exercises; (2) specific respiratory exer-
cises for 30 min (relaxation exercises for breathing muscles, 
strengthening exercises of the diaphragm with resistance, 
exercises to increase costal or chest breathing, prolonged 
exhalation exercise, and chest percussion); (3) training on a 
cycle ergometer or treadmill for 20 to 30 min at an intensity 
of 30% to 80% of peak work rate according to individual 
tolerance27; (4) resistance exercise intensity 40% to 70% of 
the 1 repetition maximum (1RM)19; (5) Nordic walking for 
45 min (depending on weather and health condition of the 
patient); and (6) relaxation training. Heart rate and oxygen 
saturation were monitored continuously throughout the 
sessions by pulse oximetry. Exercise blood pressure was as-
sessed intermittently.
Exercise training sessions were withheld in the follow-
ing situations related to cancer chemotherapy: 24 hr after 
chemotherapy; anemia (hemoglobin <8 g/L); neutropenia 
(white blood cell count <0.5 × 109 cells/μL); thrombocy-
topenia (platelet count <50 × 109μL); participants com-
plaining of nausea, vomiting, fatigue, disturbances of orien-
tation, visual disturbances, weakness, and muscle or bone 
pain within the past 24 hr.
STATISTICAL ANALYSIS
The normality of the data was evaluated using the Shap-
iro-Wilk test. The Student t test was used for normally dis-
tributed data and equal variances, and the Wilcoxon signed 
rank test was used for non-normally distributed data with 
a statistically significant P value of < .05. To make inter-
group comparisons of changes, the Mann-Whitney U test 
was adopted. The effect sizes (the Cohen d) of the differenc-
es were calculated (small ≤ 0.5, medium if ≤ 0.8, and large 
> 0.8). To evaluate the changes for each of the measured 
parameters before and after intervention in both groups, 
the relative (percent) change rate was used.
Prior to the start of the study, a statistical power analy-
sis was carried out to calculate sample size. This procedure 
determined that 19 participants were needed to achieve a 
statistical power of 90% to detect a medium effect (d = 
0.796) in the principal variable to be compared (Fullerton 
Up and Go) when assessed by a 2-tailed t test for depen-
dent variables with a level of significance of 5%. Finally, 
we selected 20 participants to ensure account for drop-
outs. The assessment was conducted by 2-sided tests. All 
calculations were performed with Statistica software v.12 
(Dell).
RESULTS
The characteristics of the patients in both the ETG and the 
CG were closely matched in terms of gender, age, weight, 
and height (Table 1). As indicated in the Consort diagram 
(Figure 2), of the 26 patients randomized to the ECG, 20 
completed the 4-wk training program and underwent the fi-
nal assessment. Of the 14 participants enrolled in the CG, 
10 completed the study. Four in the ETG and 3 in the CG 
did not complete the study because of chemotherapy-related 
events (anemia, myalgia, asthenia, pneumonia, or renal insuf-
ficiency); 2 in the ETG did not complete the study (1 death; 1 
not motivated to continue) after completing 2 wk of training. 
No adverse events related to exercise training were noted in 
the ETG group.
Table 2 summarizes the Fullerton test results. In the 
ETG, values for the chair sit and reach (P = .45, effect size 
0.04) and back scratch (P = .39, effect size 0.04) tended to 
improve, but these changes did not reach statistical signif-
icance. The 6MWT distance improved significantly in the 
ETG (P = .01, effect size 0.47). In the Up and Go Test, there 
was a statistically significant reduction in the time needed 
to complete the task (P = .01, effect size 0.23). In the chair 
stand (P < .001, effect size 0.33) and arm curl (P = .001, 
effect size 0.61), there was a statistically significant im-
provement in repetitions.
In the CG, none of the changes in the component tests 
showed a statistically significant improvement. In the chair 
sit and reach (P = .02, effect size 0.33) and up and go 
(P = .046, effect size 0.54), there was a statistically signif-
icant decrease in performance. In between-group compar-
isons, the Up and Go Test differences achieved statistical 
significance; the 6MWT distance differences approached 
significance (Table 2).
In the ETG, a statistically significant improvement in 
FEV1 % pred. (P = .01, effect size 0.56), FVC % pred. (P = 
.01, effect size 0.64), and FEV1/FVC (P = .04, effect size 
0.29) were observed (Table 3). Significant changes were 
seen in the CG only in the FEV1/FVC (P = .03, effect size 
0.79) (Table 3).
The mean values of the mMRC questionnaire (P = .18, 
effect size 0) and BDI scale in the ETG were not significantly 
improved (P = .83, effect size 0). The Borg Dyspnea Scale 
(P = .04, effect size 0.12) showed a significant improve-
ment in the perception of dyspnea in the ETG. In the CG, 
the mMRC (P = 1, effect size 0.38), BDI (P = .72, effect 
size 0.04), and the Borg dyspnea scale (P = .42, effect size 
0.83) showed nonsignificant decreases (Table 4).
Figure 2. Consolidated Standards for Reporting of Trials (CONSORT) flow diagram.
Table 2
Baseline and 6-wk Fullerton Test Results for Both Groupsa
Exercise Training Group Control Group
Between-Group Comparison,  
% Change
Before PR After PR
P 
Value
Cohen’s 
d Baseline
6-wk 
Follow-up
P 
Value
Cohen’s 
d ETG CG
P 
Valueb
Arm curl, repetitions 18.4 ± 3.1 20.4 ± 3.5 .001 0.61 15.2 ± 3.0 16.2 ± 3.3 .06 0.33 11.8 ± 13.4
6.9 ± 9.7
.36
Chair stand, repetitions 13.3 ± 2.8 14.3 ± 3.4 .01 0.33 11 ± 1.8 11.2 ± 1.5 .34 0.12 7.2 ± 9.2
2.4 ± 6.0
.17
Chair sit and reach, cm 1.9 ± 6.6 2.2 ± 6.2 .45 0.04 −3.3 ± 3.6 −4.4 ± 3.4 .02 0.33 −3.3 ± 15.1
−14.7 ± 105.1
.20
Up and go, sec 6.3 ± 1.0 6.0 ± 1.1 .01 0.23 6.0 ± 0.4 6.3 ± 0.8 .046 0.54 3.8 ± 6.4
−5.3 ± 7.3
.01
Back scratch, cm − 1.8 ± 7.1 −1.5 ± 7.2 .39 0.04 −9.1 ± 6.1 −8.1 ± 4.6 .36 0.2 −5.0 ± 45.9
3.8 ± 20.6
.52
6MWT, m 486 ± 92 531 ± 103 .01 0.47 487 ± 100 490 ± 124 .92 0.02 10.4 ± 17.4
0.3 ± 15.4
.09
Abbreviations:  CG, control group; ETG, exercise training group; PR, rehabilitation program; 6MWT, 6-min walk test.
aData reported as mean ± standard deviation.
bMann-Whitney U test was used the calculate P values.
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DISCUSSION
This study is among the few studies evaluating the effects 
of an exercise training program in patients with advanced 
NSCLC during chemotherapy.28 In the last decade, growing 
interest has been noted in research on different forms of PR, 
including physiotherapy, in patients with lung cancer. Most 
of these studies have focused on perioperative physiothera-
py, including the Cochrane database review.29-32
Chronic obstructive pulmonary disease often coexists 
with lung cancer.33 A PR program designed for patients 
with COPD19 was adopted in this study. Research conduct-
ed over many years in the field of physiotherapy in COPD 
clearly shows its positive impact.12,19,34-38
Several systematic reviews conclude that exercise train-
ing is safe in lung cancer and even increases functional ca-
pacity,28,39-41 but only a few studies in patients with newly 
diagnosed advanced lung cancer during chemotherapy were 
evaluated.17,42-47 From 2004 to 2007, Temel et al42 enrolled 
25 patients with NSCLC, of whom only 11 (44%) completed 
the entire rehabilitation program. The authors used aerobic 
Table 3
Baseline and 6-wk Spirometry Test Results for Both Groupsa
Exercise Training Group Control Group Between-Group Comparison, % Change
Before PR After PR
P 
Value
Cohen’s 
d Baseline
6-wk 
Follow-up
P 
Value
Cohen’s 
d ETG CG
P 
Valueb
FEV1, % pred 76 ± 16 84 ± 15 .01 0.56 70 ± 23 68 ± 24 .68 0.11 14 ± 21 −0.9 ± 15.1 .08
FVC, % pred 87 ± 14 95 ± 13 .01 0.64 80 ± 21 80 ± 22 .83 0.04 9 ± 13.9 0.4 ± 10.1 .06
FEV1/FVC, % 70 ± 13 76 ± 12 .04 0.29 82 ± 17 71 ± 12 .03 0.79 9,3 ± 15.8 −9,5 ± 11.7 .01
Abbreviations: FEV1, forced expiratory volume in 1 sec; FEV1/FVC, forced expiratory volume in 1 sec as a percent of vital capacity; FVC, forced vital capacity; PR, pulmonary rehabilitation.
aData are reported as mean ± standard deviation.
bMann-Whitney U test was used to calculate P values.
Table 4
Evaluation of Dyspneaa
Exercise Training Group Control Group
Between-Group Comparison,  
% Change
Before PR After PR P Value Cohen’s d Baseline
6-wk 
Follow-up P Value Cohen’s d ETG CG P Valueb
mMRC 0.7 ± 0.9 0.7 ± 1.0 .18 0 0.6 ± 1.0 0.3 ± 0.7 1 0.38 0.7 ± 0.9 0.7 ± 1.0 .18
FI 3.2 ± 0.8 3.1 ± 0.9 1 0.06 3.3 ± 0.9 3.3 ± 0.8 .72 0 3.2 ± 0.8 3.1 ± 0.9 1
MT 3.3 ± 0.7 3.3 ± 0.9 1 0 3.3 ± 0.9 3.3 ± 0.8 1 0 3.3 ± 0.7 3.3 ± 0.9 1
ME 3.1 ± 0.8 3.1 ± 0.9 .80 0 3.3 ± 0.8 3.2 ± 0.9 .96 0.12 3.1 ± 0.8 3.1 ± 0.9 .80
BDI 9.5 ± 2.1 9.5 ± 2.4 .83 0 9.9 ± 2.6 9.8 ± 2.4 .72 0.04 9.5 ± 2.1 9.5 ± 2.4 .83
Borg 1.7 ± 2.2 1.5 ± 2.1 .04 0.12 1.1 ± 1.0 2.6 ± 2.5 .42 0.83 1.7 ± 2.2 1.5 ± 2.1 .04
Abbreviations: BDI, Baseline Dyspnea Index (BDI=FI+MT+ME); Borg, Borg Dyspnea Scale; FI, functional impairment; ME, magnitude of effort; mMRC, modified Medical Research Council 
Questionnaire; MT, magnitude of task; PR, pulmonary rehabilitation.
aData are reported as mean ± standard deviation.
bMann-Whitney U test.
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training and weight training for 90 to 120 min twice weekly 
for 8 wk. The authors demonstrated nonsignificant increas-
es in the average 6MWT distance and muscle strength.42 
A similar study was performed by a Polish group of inves-
tigators assessing the utility of a PR program on mobility, 
dyspnea, and lung function in patients with advanced lung 
cancer during chemotherapy. The study group consisted 
of 20 patients (a study group of 12, a CG of 8). Only 12 
underwent the final assessment (60%). The 8-wk inpatient 
rehabilitation program was based on Nordic walking ex-
ercise training and respiratory muscle training 5 times/wk. 
The authors observed an increase in the average distance 
in the 6MWT, FEV1, and perception of dyspnea with the 
MRC questionnaire.43 Hwang et al47 enrolled 24 patients 
with NSCLC (stages IIIa-IV), who were randomly assigned 
to either the CG or the exercise group. The exercise train-
ing consisted of treadmill or cycling ergometer performed 
3 times/wk for 24 sessions; each exercise session was 30 to 
40 min in length. The authors demonstrated a significant 
increase in the peak oxygen uptake and % predicted peak 
oxygen uptake and decreased dyspnea.47
Tarumi et al48 investigated the changes in respiratory 
function because of a perioperative intensive PR program 
in patients with NSCLC who underwent induction chemo-
radiotherapy. A group of 82 patients with NSCLC IIB-IV 
stage underwent a PR program for an average of 10 wk. 
Significant increases were observed in FEV1 and FVC.48
Compared to previous studies, 26 patients were random-
ized to the intervention group, and 20 underwent the final 
assessment (77%) in our study. Our results suggest good 
tolerance of exercise training by patients with lung can-
cer. The favorable outcomes indicated by our results could 
be because of the exercise training program at the study 
hospital, which consisted of high-intensity exercise (activ-
ities that occurred 5 times/wk; daily patient participation 
ranged from 120 to 170 min, depending on the model of 
rehabilitation used) over a shorter duration (the exercise 
training program lasted 4 wk). In our study, the statisti-
cally significant improvement in the 6MWT distance is the 
result of the rehabilitation adhering to the recommenda-
tions of the American College of Sport Medicine,19 which 
posits that aerobic training should be carried out 3 to 
5 times/wk to have a positive impact on improving physical 
capacity. The results of our study correspond to the results 
of Licker et al,49 who investigated the effects of high-intensi-
ty interval training in patients awaiting lung cancer surgery. 
Those results showed a significant improvement in aerobic 
performance expressed as 6MWT distance.49 Appropriate 
qualifications for rehabilitation, including a functional as-
sessment of the patient, contributed to the proper selection 
of load and intensity of training, and thereby to the choice 
of the appropriate model of rehabilitation according to the 
individual abilities of the patient, which seems to be lacking 
in previous studies.
In the assessment of the results of exercise training in pa-
tients with lung cancer, the Fullerton test was used because 
of the advanced age of the patients. A statistically signif-
icant improvement was observed in the Up and Go Test, 
which is also commonly used for patients with COPD to 
assess dynamic balance and coordination, directly affecting 
the risk of falls.50-52 This is important in patients with lung 
cancer treated with chemotherapy, in whom balance prob-
lems are often observed as a side effect of chemotherapy. A 
statistically significant improvement was also observed in 
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the arm curl and chair stand tests. This is consistent with 
the study by Quist et al,44 which also reported a signifi-
cant improvement in muscle strength in a nonrandomized 
study with 71 patients with advanced-stage lung cancer 
(NSCLC, stage IIIb-IV). These findings also correspond 
with the results described by Adamsen et al,53 Salhi et al,54 
and Kuehr et al.55 These results are in contrast to those of 
previous studies reporting no change in muscle strength in 
patients with NSCLC. In a study by Temel et al,42 which 
included 25 patients with advanced NSCLC who under-
went a structured exercise program, the authors found no 
deterioration in their 6MWT or muscle strength. Arbane 
et al30 proposed a 12-wk rehabilitation program for patients 
undergoing lung resection for NSCLC. Post-operative data 
showed a change in quadriceps strength from baseline to 
12 wk, but this was not statistically significant.30
We observed a deterioration in functional fitness within 
the CG. A significant decrease in the Up and Go Test and 
the Chair Sit and Reach Test compared with baseline was 
observed.
This study has revealed that exercise training is benefi-
cial for lung capacity. The patients in the exercise group 
displayed significant improvements in FEV1, FVC, and 
FEV1/FVC. In contrast to our data, Andersen et al46 reported 
no change in FEV1 and FEV1 % predicted after 7 wk of 
twice weekly training in 21 patients with lung cancer.
Decreased dyspnea was also noted in the ETG; however, 
a significant improvement in dyspnea was observed only in 
the Borg scale in contrast to the CG, who showed a nonsig-
nificant increase of dyspnea.
The strength of our study was the inclusion of a CG. A 
limitation of this study was the relatively small number of 
people enrolled and the lack of biochemical marker mea-
surements in the ETG compared with the CG. Indeed, we 
cannot exclude the effect of exercise training on reducing 
fatigue symptoms and increasing exercise tolerance. Our 
results require confirmation by a larger multicenter study. 
The individual exercise training program could be intro-
duced in the first phase of treatment in patients with lung 
cancer. The results of this study on the role of exercise train-
ing in reducing fatigue symptoms show that this method 
could be an important part of the rehabilitation program in 
patients with advanced lung cancer during chemotherapy.
CONCLUSION
This study suggests that planned, individualized, and su-
pervised exercise programs in patients with advanced lung 
cancer during chemotherapy are a practical and beneficial 
intervention for enhancing mobility and physical fitness.
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